Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment

Asthma Clinical Trial

Official title:

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05642806
• Other study ID #: H20-03358
• Status: Recruiting
• Phase: Phase 4
• Start date: July 1, 2023
• Est. completion date: June 30, 2025

Study information

• Verified date: April 2024
• Source: St. Paul's Sinus Centre
• Contact: Atenea Pascual, PhD
• Phone: 604-806-9926
• Email: apascual[@]providencehealth.bc.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to analyze the immune profiles of patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) with and without asthma before and after Mepolizumab.

A group of participants with CRS without nasal polyps (CRSsNP) with asthma will be included to compare their immune profiles to CRSwNP.

Description:

The proposed design is a 24-week randomized, double-blind, placebo-controlled, parallel-group study to compare the molecular profiles of CRSwNP patients with or without asthma after Mepolizumab treatment. Subjects must sign an informed consent before any study-related procedure is performed. At visit 1 (Screening) nasoendoscopy procedure, blood test analysis, and asthma history evaluation will be performed for all subjects. Newly diagnosed asthma patients will be confirmed by specific tests (methacholine and atopy test) between screening and baseline visits. Subjects who meet eligibility criteria at Visit 2 (Baseline) will be randomized to receive either mepolizumab or placebo in addition to standard-of-care CRS treatment using block randomization through REDCap. This study will be blinded to the PI, the patient, and one of the research coordinators. The blinded research coordinator will be responsible for randomizing the study subjects using REDCap.

In this visit, a nasal sample will be collected to measure the analysis of the inflammatory cytokine from the nasal secretions. This procedure will be repeated in the middle and end of treatment (week 8 and week 24). During the blind-treatment run-in period, study treatment will be administered at St Paul's Hospital every 4 weeks for 6 months. Participants will complete different questionnaires to measure the symptoms and social/emotional consequences of the subject's nasal disorder (SNOT- 22), health-related quality of life EuroQol-5 (EQ-5D), and an objective smell identification test (SIT). They will assess their global impression of change since starting the study drug using the Patient Global Impression of Change (PGIC) scale.

This study will also include 30 participants with CRSsNP with asthma that will not undergo any study procedure except the Screening and Baseline Visit to collect a nasal sample for cytokine analysis. These results will later be compared to those who positively responded to Mepolizumab.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: June 30, 2025
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Are over the age of 19.

2. Patients with CRSwNP with or without asthma:

• Asthma confirmed with a spirometry and assessment on previous history of asthma (a methacholine challenge test and atopy testing to document positive or negative history of asthma will be performed if there is no clinical record).

• Presence or absence of nasal polyps. This can be based on formal exam at Baseline Visit or historical assessment.

3. Patients with CRSsNP with asthma:

• These patients will not take the study treatment and they will only complete screening and baseline visits.

4. Females of childbearing potential must commit to using an acceptable method of birth control for the duration of the study and they must have a negative urine pregnancy test at each study visit.

Exclusion Criteria:

1. Current or past sinonasal or bronchial tumours

2. Subjects who have been treated with oral antibiotics in the past month prior to surgery.

3. Subjects with known immunodeficiency

4. Subjects with known autoimmune disease

5. Smoking history; current or former smokers.

6. Prior lung transplants

7. Subjects with parasitic (helmintic) infection

8. Subjects with hypersensitivity; with allergy/intolerance to a monoclonal antibody or biologic

9. Female participants who are pregnant or breastfeeding

Related Conditions & MeSH terms

• Asthma
• Chronic Rhinosinusitis With Nasal Polyps
• Chronic Rhinosinusitis Without Nasal Polyps
• Nasal Polyps
• Polyps
• Rhinosinusitis
• Sinusitis

Intervention

Biological:
• Mepolizumab
Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks

Other:
• Placebo
Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks

Locations

Country	Name	City	State
Canada	St. Pual's Sinus Centre	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
St. Paul's Sinus Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare the immune profile in CRSwNP patients with and without asthma (before and after Mepolizumab treatment), and with asthmatic CRSsNP patients.	• Mean change from baseline in key inflammatory cytokines measured by the Luminex Bio-Plex Pro Human Cytokine Multi-Plex (the specific cytokine targets for this assay include: IL-1ß, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, basic FGF, eotaxin, G-CSF, GM-CSF, IFN?, IP-10, MCP-1 (MCAF), MIP-1a, MIP-1ß, PDGF-BB, RANTES, TNF-a, VEGF)	24 weeks
Secondary	Explore the effects of Mepolizumab compared to placebo in the treatment of Chronic Rhinosinusitis	Mean change from baseline in Modified Lund-Kennedy (MLK) endoscopic scores	24 weeks
Secondary	Explore the effects of Mepolizumab compared to placebo in the treatment of Chronic Rhinosinusitis	Mean change from baseline in the 22-item Sino Nasal Outcome Test (SNOT-22)	24 weeks
Secondary	Examine the treatment response to Mepolizumab in CRSwNP patients with and without asthma.	Mean change from baseline in MLK	24 weeks
Secondary	Examine the treatment response to Mepolizumab in CRSwNP patients with and without asthma.	Mean change from baseline in SNOT-22	24 weeks